The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.
PMID: 17438047
2007
Antimicrobial agents and chemotherapy
Abstract: Analysis of a large sequence database revealed that rtL80V/I occurred almost exclusively in association with LMV resistance, and 85% of these isolates encoded rtL80I.
Abstract: Collectively, these results suggest that coselection of rtL80V/I and rtM204I/V occurs because the former compensates for the loss of replication efficiency associated with the acquisition of LMV resistance, particularly in the case of rtM204I.
Abstract: Coselection of rtL80V/I occurred in 46% of isolates in which LMV resistance was attributable to
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.
PMID: 17913933
2007
Journal of clinical microbiology
Abstract: A compensatory mutation at position rt80 (L80V/I) was detected in half of these patients.
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
PMID: 17567633
2007
The Journal of antimicrobial chemotherapy
Abstract: All but three patients had baseline rtM204I/V substitutions associated with rtL180M in 23, rtL80I/V in 14, rtV173L in 4, rtT184S in 3, rtQ215S in 2 and rtA181S in 2 cases.
HBV mutation literature information.
PMID: 
2007
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT